Abstract
In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.
| Original language | English |
|---|---|
| Type | Blog entry |
| Media of output | BMJ Opinion blog |
| Publication status | Published - 19 Jul 2019 |
Publication series
| Name | BMJ Blogs |
|---|
Fingerprint
Dive into the research topics of 'Implications of “No Deal” Brexit for Orphan and Paediatric Medicines'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver